Table 2.
Correlations between the clinical and pathological features and ESRD in the univariate and multivariate Cox regression analyses.
| Baseline data | Univariate hazard ratio (95% CI) | P value | Multivariate hazard ratio (95% CI) | P value |
|---|---|---|---|---|
| Clinical findings | ||||
| Age (baseline < 20 years, per 10-year increase) | 1.26 (1.06–1.50) | 0.01 | 0.82 (0.66–1.03) | 0.09 |
| Sex (male, vs. female) | 2.08 (1.32–3.29) | 0.002 | 1.38 (0.84–2.27) | 0.20 |
| BMI (baseline < 20 kg/m2, per 1-kg/m2 increase) | 1.09 (1.01–1.17) | 0.03 | 0.95 (0.88–1.03) | 0.25 |
| MAP (baseline < 90 mmHg, per 10-mmHg increase) | 1.28 (1.04–1.58) | < 0.001 | 1.31 (1.07–1.62) | 0.009 |
| Laboratory findings | ||||
| eGFR (baseline ≥ 90 mL/min, per 30-ml/min decrease) | 4.33 (3.13–6.05) | < 0.001 | 4.88 (3.26–7.33) | < 0.001 |
| Proteinuria (baseline ≤ 0.5 g/day, per 0.5-g/day increase) | 1.13 (1.10–1.16) | < 0.001 | 1.17 (1.12–1.21) | < 0.001 |
| Haematuria (baseline < 5/HPF, per 25/HPF increase) | 0.98 (0.85–1.12) | 0.80 | ||
| Histological findings | ||||
| Oxford classification grade (O-grade) | 2.43 (1.66–3.56) | < 0.001 | 1.63 (1.11–2.38) | 0.012 |
| Treatments | ||||
| Corticosteroids/immunosuppressors | 0.67 (0.42–1.06) | 0.08 | 0.46 (0.27–0.80) | 0.005 |
| RAS inhibitors | 1.01 (0.63–1.62) | 0.96 | 0.69 (0.40–1.18) | 0.17 |
95% CI 95% confidence interval, BMI body mass index, MAP mean arterial blood pressure, HPF high-power field, ESRD end-stage renal disease, O-grade a new grading system utilising the total score of each variable in the Oxford classification (MEST-C) and the renal survival rate, RAS renin-angiotensin system.